Garth Lees-Rolfe
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Garth Lees-Rolfe
Earlier roles on record: CFO at Inhibikase Therapeutics, Inc. (IKT) until April 11, 2025. Inhibikase Therapeutics, Inc. reported in an 8-K filed April 14, 2025 that Garth Lees-Rolfe resigned as Chief Financial Officer, principal financial officer and principal accounting officer, effective April 11, 2025. The proxy statement of Inhibikase Therapeutics, Inc. reports total compensation of $1,210,184 for Garth Lees-Rolfe in fiscal 2024, including a base salary of $306,990. Garth Lees-Rolfe has spoken on 3 earnings calls across 1 company, most recently for Inhibikase Therapeutics, Inc. on June 30, 2024.
“Effective April 11, 2025, Garth Lees-Rolfe resigned as Chief Financial Officer, principal financial officer and principal accounting officer of Inhibikase Therapeutics, Inc. (the “Company”).”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2025-04-11
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Inhibikase Therapeutics, Inc. (IKT) | Former Chief Financial Officer | $306,990 | $1,210,184 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.